arrow
M

Marie Fallon

University of Edinburgh
H指数:57
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparing the effectiveness, cost-effectiveness and implementation of low-dose oral modified release morphine in people with chronic breathlessness: a synopsis of a RCT and process evaluation

比较低剂量口服缓释吗啡在慢性呼吸困难患者中的疗效、成本效益及实施情况:一项随机对照试验和过程评估的概要

2026-05-010
PRE
Adaptation of digital integration of PROMs and PREMs in oncology during implementation: a scoping review

数字整合患者报告结局和患者报告体验测量在肿瘤学实施过程中的适应性:一项范围综述

2026-03-130
OAAI
Balancing ideals and realities: health care professionals’ perspectives of and attitudes toward digital patient-centered cancer care

平衡理想与现实:卫生保健专业人员对数字患者为中心的癌症护理的观点和态度

2026-02-180
OAAI
Morphine for chronic breathlessness (MABEL) in the UK: a health economic evaluation of a multisite, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial

英国的吗啡治疗慢性呼吸困难 (MABEL): 对多站点,平行组,剂量滴定,双盲,随机,安慰剂对照试验的健康经济学评估

2025-11-050
OA
Investigation of an integrated standardised pain assessment and management tool in addition to usual care versus usual care alone in oncology outpatient clinics for adults with pain: the CAPTURE cluster randomised pilot trial protocol. ISRCRN86926298
2025-10-300
OAAI
Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial

英国慢性呼吸困难 Morphine 治疗(MABEL)研究:一项多中心、平行组、剂量滴定、双盲、随机、安慰剂对照试验

2025-09-280
OAAI
The Global Leadership Initiative on Malnutrition (GLIM) inflammation criteria to predict survival in patients with advanced cancer: A prospective cohort study

全球营养不良领导倡议(GLIM)炎症标准在预测晚期癌症患者生存中的应用:一项前瞻性队列研究

2025-06-010
OAAI
Practical cancer nutrition, from guidelines to clinical practice: a digital solution to patient-centred care

实用癌症营养学:从指南到临床实践——一种面向患者中心的数字化解决方案

2025-04-011
OAAI
Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II study

庞塞格罗玛单抗(ponsegromab)的疗效和安全性评估:该药物为一种首创的单克隆抗体抑制剂,可抑制生长分化因子15,用于癌症恶病质患者的研究:一项随机、安慰剂对照的II期临床试验

2024-09-010
PRE
Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series
2024-05-234
OA
Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series

癌症恶病质临床试验中的体重及身体成分终点:恶病质终点系列之系统综述第4篇

2024-05-132
OAAI
Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series

癌症恶病质临床试验中的生活质量终点:恶病质终点系列研究之三

2024-03-292
OAAI
Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series

癌症恶病质临床试验的食欲和饮食摄入终点: 恶病质终点系列的系统评价2

2024-02-115
OAAI